70 citations
,
September 2017 in “Expert opinion on therapeutic patents” The review suggests that while many AKR1C3 inhibitors show promise for treating certain cancers, more research is needed to confirm their effectiveness in humans.
26 citations
,
October 2011 in “International Journal of Biological Macromolecules” Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.
2 citations
,
November 2018 in “Indian Journal of Pharmaceutical Education” The developed model can predict effective 5-alpha-reductase enzyme inhibitors.
6 citations
,
May 2020 in “JAMA Ophthalmology” Using 5-alpha-reductase inhibitors, drugs for prostate issues and hair loss, may lead to eye abnormalities in men.
21 citations
,
March 2018 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” 5-alpha-reductase inhibitors may help stabilize or slow down hair loss in some frontal fibrosing alopecia patients, but more research is needed to confirm their effectiveness and safety.
17 citations
,
December 2004 in “Bioorganic & Medicinal Chemistry Letters” Scientists found new, better-working inhibitors for a hormone-related enzyme.
3 citations
,
August 2010 in “Letters in Drug Design & Discovery” June 2021 in “F1000Research” Plant-based compounds may offer safer prostate cancer treatment with fewer side effects.
August 2019 in “The Journal of Urology” Treatment with 5α-reductase inhibitors is linked to a delay in prostate cancer diagnosis and may affect survival rates.
3 citations
,
July 2021 in “Drug Testing and Analysis” 5α-reductase inhibitors can interfere with doping tests by masking banned substances.
September 2025 in “Journal of the American Academy of Dermatology” Using 5α-reductase inhibitors for hair loss in women doesn't increase cancer risk.
January 2002 in “映像情報メディア学会技術報告” Some prostate cancers have gene changes that may affect treatment with certain drugs.
4 citations
,
August 2010 in “Acta Biologica Hungarica” New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.
January 2014 in “프로그램북(구 초록집)” 5AR inhibitors like finasteride and dutasteride improve hair growth and slow hair loss in male pattern baldness.
2 citations
,
December 2021 in “International Journal of Andrology” Most legal cases about 5α-reductase inhibitors, drugs for hair loss and prostate issues, complain about side effects and delayed cancer diagnosis, with most lawsuits settled out of court.
11 citations
,
August 2009 in “Expert Opinion on Drug Discovery” We need better ways to test and understand SARMs to make safer and more effective treatments.
78 citations
,
December 2008 in “The Journal of Sexual Medicine” 5-alpha reductase inhibitors can cause sexual side effects like erectile dysfunction, but the exact reasons are unclear.
January 2006 in “Zhongguo yaofang” The market for these drugs is expected to grow.
June 1993 in “Current opinion in therapeutic patents” Hexahydrobenzo[f]quinolines are effective at blocking the enzyme 5α-reductase.
13 citations
,
July 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Four drugs were found that could potentially treat COVID-19 by inhibiting the virus in lab tests.
18 citations
,
January 2001 in “Annual Reports in Medicinal Chemistry” Selective Androgen Receptor Modulators (SARMs) are drugs that can control the effects of androgens in different tissues, potentially having fewer side effects and promising for treating various conditions.
1 citations
,
September 2016 in “Actas Dermo-Sifiliográficas” 5-alpha reductase inhibitors may cause sexual side effects, breast complications, and other health risks in men with hair loss.
47 citations
,
November 2012 in “Expert Opinion on Therapeutic Patents” The document concludes that research on sulfatase inhibitors should continue due to their potential in treating various diseases, despite some clinical trial failures.
90 citations
,
March 2017 in “JAMA Internal Medicine” Men over 66 taking medication for prostate enlargement have a higher risk of depression and self-harm, especially in the first 18 months of treatment.
5 citations
,
January 2001 in “Advances in protein chemistry” 5α-reductase inhibitors help treat disorders caused by DHT and have potential for future therapies.
October 2010 in “Journal of Men's Health” The conclusion is that doctors should be careful when prescribing 5α-reductase inhibitors due to possible serious side effects, and they should discuss these risks with patients.
Low-dose sorafenib can cause severe facial acne, treatable with topical medication.
2 citations
,
July 2006 in “European Urology Supplements” 5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.
February 2026 in “Toxicology Letters” MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.
219 citations
,
October 2009 in “Steroids” 5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.